Fundz

Exsilio Therapeutics raised $82 million in a Series A financing co-led by Novartis Venture Fund and Delos Capital

PRIVATEJun 25, 2024

Amount Raised

$82 Million

Round Type

Series A

New YorkHealthcareHealth Care

Investors

Deep InsightArc VenturesInvusInnovation EndeavorsCrispr TherapeuticsJ.P. Morgan Life Sciences Private CapitalInsight PartnersOrbi MedDelos CapitalNovartis Venture Fund

Description

Exsilio Therapeutics, a biotechnology company focused on developing genomic medicines for genetic diseases, cancer, and autoimmune conditions, emerged from stealth with $82 million in Series A financing. The funding was co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight.

Who to call at Exsilio Therapeutics, and when

A new round usually means Exsilio Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Exsilio Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Exsilio Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Exsilio Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Exsilio Therapeutics

Location

New York, New York, United States

About

Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. Exsilio’s technology is based on naturally occurring genetic elements that can precisely insert new genes into a cell through RNA intermediate templates. Exsilio uses predictive in silico modeling and wet lab-based experimentation to engineer such elements for precise insertion of therapeutic genes into safe harbor sites of disease-relevant cells. Because Exsilio’s medicines are encoded in mRNA, they can be delivered using validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, and that allow redosing to effect with a curative intent.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Exsilio Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Predictive Intelligence
Strategic

ML-powered predictions for Exsilio Therapeutics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Exsilio Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.